Ovilow Tablet contains a combination of Ethinyl Estradiol (0.02 mg) and Levonorgestrel (0.10 mg), which are synthetic hormones used primarily for contraceptive purposes. Ethinyl Estradiol is a synthetic estrogen, while Levonorgestrel is a synthetic progestin; together, they work by inhibiting ovulation, altering the cervical mucus to prevent sperm penetration, and modifying the endometrial lining to reduce the likelihood of implantation. Ovilow is indicated for the prevention of pregnancy in women seeking effective contraception. It may also be prescribed for menstrual regulation, treatment of dysmenorrhea, and management of certain hormonal imbalances. The tablet is typically administered orally once daily, preferably at the same time each day, to maintain consistent hormone levels and maximize efficacy. Patients should be counseled on the importance of adherence to dosing schedules and informed about potential side effects, which may include nausea, headache, breast tenderness, and breakthrough bleeding. Contraindications include a history of thromboembolic disorders, hormone-sensitive malignancies, unexplained vaginal bleeding, and liver dysfunction. Ovilow Tablet should be used under medical supervision, with periodic evaluation to monitor for adverse effects and ensure continued suitability for the patient’s health status.